Astrazeneca's covid-19 vaccine doesn't raise the risk of a rare blood clotting disorder after a second dose, suggesting people shouldn't hesitate to get another one if they didn't have trouble after the first.
The estimated rate of the disorder, called thrombosis with thrombocytopenia syndrome (TTS), was 2.3 per million in people who received a second shot, according to data published in the medical journal The Lancet. That's comparable to what's found in an unvaccinated population. But the rate after a single dose was still higher, at 8.1 per million.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Rumored purchase of GN Group could mean divestment of hearing aid division, says media
Inside Business has learned that a number of buyers might be looking to buy GN Store Nord stock while it’s cheap, with the plan to sell one division, GN Hearing, while keeping Audio.
EMA publishes new plan to support antibiotic development
Drug-resistant bacteria kill hundreds of thousands of people every year, and national regulatory forces across the world are now coming together to ensure a uniform approach to clinical trials for antibiotics.
Director of Toxicology 
Client Talent Acquisition Specialist 
Senior Project Manager (GMP - Life Science) 
(Senior) Drug Substance Specialist 
Senior IT Network Engineer 
Account Manager 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Communications Consultant 
Director for innovative pre-clinical testing unit 
Scientific Writer 
Key Account Manager, Europe and Asia 
Senior Chemical Safety Advisor 
Industrial Designer- Design Engineer 
Production Director 
Analytical Coordinator for Analytical Development 
IRT Manager, Clinical Drug Supply 
Clinical Project Manager 
Nordic Medical Affairs Manager